Page 718 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 42 Sickle Cell Disease 607.e3

97. Maggio A: Light and shadows in the iron chelation treatment of 122. Bunn HF: Pathogenesis and treatment of sickle cell disease. N Engl J
haematological diseases. Br J Haematol 138:407, 2007. Med 337:762, 1997.
98. Vichinsky E, Onyekwere O, Porter J, et al: A randomised comparison 123. Brittenham GM, Schechter AN, Noguchi CT: Hemoglobin S polym-
of deferasirox versus deferoxamine for the treatment of transfusional erization: primary determinant of the hemolytic and clinical severity of
iron overload in sickle cell disease. Br J Haematol 136:501, 2007. the sickling syndromes. Blood 65:183, 1985.
99. Neufeld EJ: Oral chelators deferasirox and deferiprone for transfusional 124. Powars DR: Natural history of sickle cell disease—The first ten years.
iron overload in thalassemia major: new data, new questions. Blood Semin Hematol 12:267, 1975.
107(9):3436–3441, 2006. 125. Sidman JD, Fry TL: Exacerbation of sickle cell disease by obstructive
100. St Pierre TG, Clark PR, Chua-Anusorn W: Measurement and mapping sleep apnea. Arch Otolaryngol Head Neck Surg 114:916, 1988.
of liver iron concentrations using magnetic resonance imaging. Ann N 126. Baum KF, Dunn DT, Maude GH, et al: The painful crisis of homo-
Y Acad Sci 1054:379, 2005. zygous sickle cell disease. A study of the risk factors. Arch Intern Med
101. Tanner MA, Galanello R, Dessi C, et al: Myocardial iron loading in 147:1231, 1987.
patients with thalassemia major on deferoxamine chelation. J Cardiovasc 127. Murray N, May A: Painful crises in sickle cell disease—Patients’
Magn Reson 8:543, 2006. perspectives. BMJ 297:452, 1988.
102. Atweh GF, Sutton M, Nassif I, et al: Sustained induction of fetal hemo- 128. Rees DC, Olujohungbe AD, Parker NE, et al: Guidelines for the man-
globin by pulse butyrate therapy in sickle cell disease. Blood 93:1790, agement of the acute painful crisis in sickle cell disease. Br J Haematol
1999. 120:744, 2003.
103. Ley TJ, DeSimone J, Noguchi CT, et al: 5-Azacytidine increases 129. Dampier CD, Setty BN, Logan J, et al: Intravenous morphine phar-
gamma-globin synthesis and reduces the proportion of dense cells in macokinetics in pediatric patients with sickle cell disease. J Pediatr
patients with sickle cell anemia. Blood 62:370, 1983. 126:461, 1995.
104. Saunthararajah Y, Hillery CA, Lavelle D, et al: Effects of 5-aza- 130. Ballas SK: Pain management of sickle cell disease. Hematol Oncol Clin
2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and North Am 19:785, 2005.
hematopoietic differentiation in patients with sickle cell disease. Blood 131. McCurdy PR: 32-DFP and 51-Cr for measurement of red cell life span
102:3865, 2003. in abnormal hemoglobin syndromes. Blood 33:214, 1969.
105. Perrine SP: Fetal globin induction—Can it cure α thalassemia? Hema- 132. Serjeant GR, Serjeant BE, Milner PF: The irreversibly sickled cell: a
tology Am Soc Hematol Educ Program 38–44, 2005. determinant of haemolysis in sickle cell anaemia. Br J Haematol 17:527,
106. Atweh GF, Schechter AN: Pharmacologic induction of fetal hemoglo- 1969.
bin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol 133. West MS, Wethers D, Smith J, et al: Laboratory profile of sickle cell
8:123, 2001. disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell
107. Moutouh-de Parseval LA, Verhelle D, Glezer E, et al: Pomalidomide Disease. J Clin Epidemiol 45:893, 1992.
and lenalidomide regulate erythropoiesis and fetal hemoglobin produc- 134. Steinberg MH, Embury SH: Alpha-thalassemia in blacks: genetic and
tion in human CD34+ cells. J Clin Invest 118:248, 2008. clinical aspects and interactions with the sickle hemoglobin gene. Blood
108. Castro O, Poillon WN, Finke H, et al: Improvement of sickle 68:985, 1986.
cell anemia by iron-limited erythropoiesis. Am J Hematol 47:74, 135. Pattison JR, Jones SE, Hodgson J, et al: Parvovirus infections and
1994. hypoplastic crisis in sickle-cell anaemia. Lancet 1:664, 1981.
109. Francis RB, Jr, Johnson CS: Vascular occlusion in sickle cell disease: 136. Rao SP, Miller ST, Cohen BJ: Transient aplastic crisis in patients with
current concepts and unanswered questions. Blood 77:1405, 1991. sickle cell disease. B19 parvovirus studies during a 7-year period. Am J
110. Ahmed S, Siddiqui AK, Iqbal U, et al: Effect of low-dose warfarin on Dis Child 146:1328, 1992.
D-dimer levels during sickle cell vaso-occlusive crisis: a brief report. Eur 137. Charache S, Page DL: Infarction of bone marrow in the sickle cell
J Haematol 72:213, 2004. disorders. Ann Intern Med 67:1195, 1967.
111. Chaplin H, Jr, Monroe MC, Malecek AC, et al: Preliminary trial of 138. Pardoll DM, Rodeheffer RJ, Smith RR, et al: Aplastic crisis due to
minidose heparin prophylaxis for painful sickle cell crises. East Afr Med extensive bone marrow necrosis in sickle cell disease. Arch Intern Med
J 66:574, 1989. 142:2223, 1982.
112. Ciurea SO, Thulborn KR, Gowhari M: Dural venous sinus thrombosis 139. Embury SH, Garcia JF, Mohandas N, et al: Effects of oxygen inha-
in a patient with sickle cell disease: case report and literature review. Am lation on endogenous erythropoietin kinetics, erythropoiesis, and
J Hematol 81:290, 2006. properties of blood cells in sickle-cell anemia. N Engl J Med 311:291,
113. Wolters HJ, ten Cate H, Thomas LL, et al: Low-intensity oral 1984.
anticoagulation in sickle-cell disease reverses the prethrombotic state: 140. Topley JM, Rogers DW, Stevens MC, et al: Acute splenic sequestration
promises for treatment? Br J Haematol 90:715, 1995. and hypersplenism in the first five years in homozygous sickle cell
114. Schnog JB, Kater AP, Mac Gillavry MR, et al: Low adjusted-dose disease. Arch Dis Child 56:765, 1981.
acenocoumarol therapy in sickle cell disease: a pilot study. Am J Hematol 141. Emond AM, Collis R, Darvill D, et al: Acute splenic sequestration
68:179, 2001. in homozygous sickle cell disease: natural history and management.
115. Greenberg J, Ohene-Frempong K, Halus J, et al: Trial of low doses J Pediatr 107:201, 1985.
of aspirin as prophylaxis in sickle cell disease. J Pediatr 102:781, 142. Hatton CS, Bunch C, Weatherall DJ: Hepatic sequestration in sickle
1983. cell anaemia. Br Med J (Clin Res Ed) 290:744, 1985.
116. Okpala I: Investigational agents for sickle cell disease. Expert Opin 143. Davies SC, Luce PJ, Win AA, et al: Acute chest syndrome in sickle-cell
Investig Drugs 15:833, 2006. disease. Lancet 1:36, 1984.
117. Telen MJ, Wun T, McCavit TL, et al: Randomized phase 2 study of 144. Talano JA, Hillery CA, Gottschall JL, et al: Delayed hemolytic trans-
GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive fusion reaction/hyperhemolysis syndrome in children with sickle cell
events and decreased opioid use. Blood 125(17):2656–2664, 2015. disease. Pediatrics 111:e661, 2003.
118. Hoban MD, Cost GJ, Mendel MC, et al: Correction of the sickle cell 145. King KE, Shirey RS, Lankiewicz MW, et al: Delayed hemolytic
disease mutation in human hematopoietic stem/progenitor cells. Blood transfusion reactions in sickle cell disease: simultaneous destruction of
125(17):2597–2604, 2015. recipients’ red cells. Transfusion 37:376, 1997.
119. Bainbridge R, Higgs DR, Maude GH, et al: Clinical presentation of 146. Petz LD, Calhoun L, Shulman IA, et al: The sickle cell hemolytic
homozygous sickle cell disease. J Pediatr 106:881, 1985. transfusion reaction syndrome. Transfusion 37:382, 1997.
120. Brozovic M, Davies SC, Brownell AI: Acute admissions of patients with 147. Smits HL, Oski FA, Brody JI: The hemolytic crisis of sickle cell disease:
sickle cell disease who live in Britain. Br Med J (Clin Res Ed) 294:1206, the role of glucose-6-phosphate dehydrogenase deficiency. J Pediatr
1987. 74:544, 1969.
121. Diggs LW: The crisis in sickle cell anemia: hematologic studies. Am J 148. Phillips G, Jr, Becker B, Keller VA, et al: Hypothyroidism in adults with
Clin Pathol 26:1109, 1956. sickle cell anemia. Am J Med 92:567, 1992.